Pathogenesis of human hemangiosarcomas and hemangiomas

Liping Liu, Satoko Kakiuchi-Kiyota, Lora L Arnold, Sonny L. Johansson, David Wert, Samuel Monroe Cohen

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Summary Hemangiosarcomas are uncommon aggressive vascular tumors that have recently become the focus of attention because several chemicals and pharmaceuticals increase their incidence in mice. The relevance of these mouse vascular tumors to humans is unclear. In the present study, we semiquantitatively evaluated the expression profiles of hematopoietic stem cell markers (CD117 [c-kit], CD133, CD34, and CD45), endothelial cell markers (vascular endothelial growth factor receptor 2, CD31, and factor VIII-related antigen), and a myeloid lineage cell marker (CD14) in human hemangiosarcoma (n = 12) and hemangioma (n = 10) specimens using immunohistochemistry. CD133 was completely negative in almost all cases of hemangiosarcomas and hemangiomas. Most hemangiosarcomas, but not hemangiomas, stained for CD117 and CD45. Both groups diffusely expressed CD34, vascular endothelial growth factor receptor 2, and factor VIII-related antigen; however, hemangiomas had more intense and diffuse CD34 and factor VIII-related antigen expression compared with hemangiosarcomas, whereas CD31 was positive in all hemangiosarcomas but only half of the hemangiomas. CD14 staining was negative in most hemangiosarcoma and hemangioma cases. Our results indicate that multipotential bone marrow-derived hematopoietic stem cells or early endothelial progenitor cells (EPCs) expressing CD117, CD34, and CD45 are involved in hemangiosarcoma formation, whereas hemangiomas originate from late EPCs or differentiated endothelial cells, which have lost the expression of most hematopoietic stem cell markers. This contrasts with our previous results that demonstrated that both hemangiosarcomas and hemangiomas in mice may be derived from early EPCs that are not completely differentiated.

Original languageEnglish (US)
Pages (from-to)2302-2311
Number of pages10
JournalHuman Pathology
Volume44
Issue number10
DOIs
StatePublished - Oct 1 2013

Fingerprint

Hemangiosarcoma
Hemangioma
von Willebrand Factor
Hematopoietic Stem Cells
Vascular Endothelial Growth Factor Receptor-2
Blood Vessels
Endothelial Cells
Negative Staining
Myeloid Cells
Neoplasms
Bone Marrow
Immunohistochemistry
Incidence

Keywords

  • Endothelial progenitor cells
  • Hemangioma
  • Hemangiosarcoma
  • Hematopoietic stem cells
  • Immunohistochemistry

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Pathogenesis of human hemangiosarcomas and hemangiomas. / Liu, Liping; Kakiuchi-Kiyota, Satoko; Arnold, Lora L; Johansson, Sonny L.; Wert, David; Cohen, Samuel Monroe.

In: Human Pathology, Vol. 44, No. 10, 01.10.2013, p. 2302-2311.

Research output: Contribution to journalArticle

Liu, L, Kakiuchi-Kiyota, S, Arnold, LL, Johansson, SL, Wert, D & Cohen, SM 2013, 'Pathogenesis of human hemangiosarcomas and hemangiomas', Human Pathology, vol. 44, no. 10, pp. 2302-2311. https://doi.org/10.1016/j.humpath.2013.05.012
Liu, Liping ; Kakiuchi-Kiyota, Satoko ; Arnold, Lora L ; Johansson, Sonny L. ; Wert, David ; Cohen, Samuel Monroe. / Pathogenesis of human hemangiosarcomas and hemangiomas. In: Human Pathology. 2013 ; Vol. 44, No. 10. pp. 2302-2311.
@article{2531d8decdab4d75b7510ac6e7faeced,
title = "Pathogenesis of human hemangiosarcomas and hemangiomas",
abstract = "Summary Hemangiosarcomas are uncommon aggressive vascular tumors that have recently become the focus of attention because several chemicals and pharmaceuticals increase their incidence in mice. The relevance of these mouse vascular tumors to humans is unclear. In the present study, we semiquantitatively evaluated the expression profiles of hematopoietic stem cell markers (CD117 [c-kit], CD133, CD34, and CD45), endothelial cell markers (vascular endothelial growth factor receptor 2, CD31, and factor VIII-related antigen), and a myeloid lineage cell marker (CD14) in human hemangiosarcoma (n = 12) and hemangioma (n = 10) specimens using immunohistochemistry. CD133 was completely negative in almost all cases of hemangiosarcomas and hemangiomas. Most hemangiosarcomas, but not hemangiomas, stained for CD117 and CD45. Both groups diffusely expressed CD34, vascular endothelial growth factor receptor 2, and factor VIII-related antigen; however, hemangiomas had more intense and diffuse CD34 and factor VIII-related antigen expression compared with hemangiosarcomas, whereas CD31 was positive in all hemangiosarcomas but only half of the hemangiomas. CD14 staining was negative in most hemangiosarcoma and hemangioma cases. Our results indicate that multipotential bone marrow-derived hematopoietic stem cells or early endothelial progenitor cells (EPCs) expressing CD117, CD34, and CD45 are involved in hemangiosarcoma formation, whereas hemangiomas originate from late EPCs or differentiated endothelial cells, which have lost the expression of most hematopoietic stem cell markers. This contrasts with our previous results that demonstrated that both hemangiosarcomas and hemangiomas in mice may be derived from early EPCs that are not completely differentiated.",
keywords = "Endothelial progenitor cells, Hemangioma, Hemangiosarcoma, Hematopoietic stem cells, Immunohistochemistry",
author = "Liping Liu and Satoko Kakiuchi-Kiyota and Arnold, {Lora L} and Johansson, {Sonny L.} and David Wert and Cohen, {Samuel Monroe}",
year = "2013",
month = "10",
day = "1",
doi = "10.1016/j.humpath.2013.05.012",
language = "English (US)",
volume = "44",
pages = "2302--2311",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "10",

}

TY - JOUR

T1 - Pathogenesis of human hemangiosarcomas and hemangiomas

AU - Liu, Liping

AU - Kakiuchi-Kiyota, Satoko

AU - Arnold, Lora L

AU - Johansson, Sonny L.

AU - Wert, David

AU - Cohen, Samuel Monroe

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Summary Hemangiosarcomas are uncommon aggressive vascular tumors that have recently become the focus of attention because several chemicals and pharmaceuticals increase their incidence in mice. The relevance of these mouse vascular tumors to humans is unclear. In the present study, we semiquantitatively evaluated the expression profiles of hematopoietic stem cell markers (CD117 [c-kit], CD133, CD34, and CD45), endothelial cell markers (vascular endothelial growth factor receptor 2, CD31, and factor VIII-related antigen), and a myeloid lineage cell marker (CD14) in human hemangiosarcoma (n = 12) and hemangioma (n = 10) specimens using immunohistochemistry. CD133 was completely negative in almost all cases of hemangiosarcomas and hemangiomas. Most hemangiosarcomas, but not hemangiomas, stained for CD117 and CD45. Both groups diffusely expressed CD34, vascular endothelial growth factor receptor 2, and factor VIII-related antigen; however, hemangiomas had more intense and diffuse CD34 and factor VIII-related antigen expression compared with hemangiosarcomas, whereas CD31 was positive in all hemangiosarcomas but only half of the hemangiomas. CD14 staining was negative in most hemangiosarcoma and hemangioma cases. Our results indicate that multipotential bone marrow-derived hematopoietic stem cells or early endothelial progenitor cells (EPCs) expressing CD117, CD34, and CD45 are involved in hemangiosarcoma formation, whereas hemangiomas originate from late EPCs or differentiated endothelial cells, which have lost the expression of most hematopoietic stem cell markers. This contrasts with our previous results that demonstrated that both hemangiosarcomas and hemangiomas in mice may be derived from early EPCs that are not completely differentiated.

AB - Summary Hemangiosarcomas are uncommon aggressive vascular tumors that have recently become the focus of attention because several chemicals and pharmaceuticals increase their incidence in mice. The relevance of these mouse vascular tumors to humans is unclear. In the present study, we semiquantitatively evaluated the expression profiles of hematopoietic stem cell markers (CD117 [c-kit], CD133, CD34, and CD45), endothelial cell markers (vascular endothelial growth factor receptor 2, CD31, and factor VIII-related antigen), and a myeloid lineage cell marker (CD14) in human hemangiosarcoma (n = 12) and hemangioma (n = 10) specimens using immunohistochemistry. CD133 was completely negative in almost all cases of hemangiosarcomas and hemangiomas. Most hemangiosarcomas, but not hemangiomas, stained for CD117 and CD45. Both groups diffusely expressed CD34, vascular endothelial growth factor receptor 2, and factor VIII-related antigen; however, hemangiomas had more intense and diffuse CD34 and factor VIII-related antigen expression compared with hemangiosarcomas, whereas CD31 was positive in all hemangiosarcomas but only half of the hemangiomas. CD14 staining was negative in most hemangiosarcoma and hemangioma cases. Our results indicate that multipotential bone marrow-derived hematopoietic stem cells or early endothelial progenitor cells (EPCs) expressing CD117, CD34, and CD45 are involved in hemangiosarcoma formation, whereas hemangiomas originate from late EPCs or differentiated endothelial cells, which have lost the expression of most hematopoietic stem cell markers. This contrasts with our previous results that demonstrated that both hemangiosarcomas and hemangiomas in mice may be derived from early EPCs that are not completely differentiated.

KW - Endothelial progenitor cells

KW - Hemangioma

KW - Hemangiosarcoma

KW - Hematopoietic stem cells

KW - Immunohistochemistry

UR - http://www.scopus.com/inward/record.url?scp=84884398871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884398871&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2013.05.012

DO - 10.1016/j.humpath.2013.05.012

M3 - Article

VL - 44

SP - 2302

EP - 2311

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 10

ER -